Article

The role of colonic metabolism in lactose intolerance

TI Food and Nutrition, Wageningen, The Netherlands.
European Journal of Clinical Investigation (Impact Factor: 2.83). 07/2008; 38(8):541-7. DOI: 10.1111/j.1365-2362.2008.01966.x
Source: PubMed

ABSTRACT Lactose maldigestion and intolerance affect a large part of the world population. The underlying factors of lactose intolerance are not fully understood. In this review, the role of colonic metabolism is discussed, i.e. fermentation of lactose by the colonic microbiota, colonic processing of the fermentation metabolites and how these processes would play a role in the pathophysiology of lactose intolerance. We suggest that the balance between the removal and production rate of osmotic-active components (lactose, and intermediate metabolites, e.g. lactate, succinate, etc.) in the colon is a key factor in the development of symptoms. The involvement of the colon may provide the basis for designing new targeted strategies for dietary and clinical management of lactose intolerance.

Download full-text

Full-text

Available from: Roel Vonk, Feb 24, 2014
0 Followers
 · 
134 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Carbohydrates are the major energy source in the body. In this review article, monosaccharides, disaccharides, sucrose, maltose, lactose, starch, dextrin, glycogen, cellulose, glycosaminoglycan, sialic acid and previous research study on carbohydrates has been given herewith
  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Abdominal symptoms linked to lactose malabsorption may be caused by metabolic activity of colonic bacteria. Rifaximin, a non-absorbable rifampycin derivative, is active against colonic bacteria, it may be useful in the treatment of lactose intolerance. The aim of this study has been to evaluate short-term rifaximin therapy in patients with lactose intolerance. Thirty-two patients with lactose intolerance diagnosed using the hydrogen lactose breath test were studied. Fourteen patients received rifaximin 800 mg/day for 10 days, 13 patients followed a diet without milk for 40 days and 5 patients received a placebo for 10 days. Total breath H(2) excretion expressed as area under the curve, and the symptom score were evaluated in all patients at the start, and subsequently after 10 and 40 days. In the 14 patients who received rifaximin for 10 days, area under the curve at day 10 and day 40 was statistically significantly lower than the one computed at basal (P<0.01). Diet reduced area under the curve progressively reaching statistical significance at day 40, while the placebo did not change area under the curve throughout the study. The total symptom score significantly improved after rifaximin and diet. In patients with lactose intolerance, a 10-day therapy with rifaximin as well as 40-day diet without lactose reduces the area under the curve and the symptom score.
    Digestive and Liver Disease 05/2005; 37(5):316-9. DOI:10.1016/j.dld.2004.12.007 · 2.89 Impact Factor